The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function

Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the identification of resistance mutations mapping to the NS5B...

Descripción completa

Detalles Bibliográficos
Autores principales: Hebner, Christy M., Han, Bin, Brendza, Katherine M., Nash, Michelle, Sulfab, Maisoun, Tian, Yang, Hung, Magdeleine, Fung, Wanchi, Vivian, Randall W., Trenkle, James, Taylor, James, Bjornson, Kyla, Bondy, Steven, Liu, Xiaohong, Link, John, Neyts, Johan, Sakowicz, Roman, Zhong, Weidong, Tang, Hengli, Schmitz, Uli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374789/
https://www.ncbi.nlm.nih.gov/pubmed/22720059
http://dx.doi.org/10.1371/journal.pone.0039163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374789/
https://www.ncbi.nlm.nih.gov/pubmed/22720059
http://dx.doi.org/10.1371/journal.pone.0039163

Ejemplares similares